Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms

Garima Pandey, Lucia Mazzacurati, Nathan P. Horvat, Tegan Rowsell, Narmin E. Amin, Guolin Zhang, Afua Adutwumwa Akuffo, Christelle M. Colin-Leitzinger, Eric B. Haura, Andrew T. Kuykendall, PK Epling-Burnette, Gary W. Reuther

Blood (2023) 142 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2023-189657

Published: 2023

Journal Articles

SHP2 Inhibition Suppresses RAS-ERK Signaling, the Development of JAK2 Inhibitor Persistence, and MPN Development in Pre-Clinical Models of Myeloproliferative Neoplasms

Garima Pandey, Nathan Horvat, Narmin E. Amin, Guolin Zhang, Lucia Mazzacurati, Afua A. Akuffo, Christelle Colin-Leitzinger, Eric B. Haura, Pearlie K. Epling-Burnette, Gary W. Reuther

Blood (2022) 140 (Supplement 1): 9573–9574.

https://doi.org/10.1182/blood-2022-160349

Published: 2022

Journal Articles

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Garima Pandey, Guolin Zhang, Narmin Amin, Lucia Mazzacurati, Eric B. Haura, Gary W. Reuther, PhD

Blood (2018) 132 (Supplement 1): 3064.

https://doi.org/10.1182/blood-2018-99-118641

Published: 2018

Journal Articles

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

Lucia Mazzacurati, Que T. Lambert, Gary W. Reuther, PhD

Blood (2017) 130 (Supplement 1): 2935.

https://doi.org/10.1182/blood.V130.Suppl_1.2935.2935

Published: 2017

Journal Articles

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Lucia Mazzacurati, Que T. Lambert, Robert J. Collins, Holly K. Koblish, PhD, Bruce Ruggeri, Matthew C. Stubbs, Gary W. Reuther, PhD

Blood (2017) 130 (Supplement 1): 1661.

https://doi.org/10.1182/blood.V130.Suppl_1.1661.1661

Published: 2017

NARROW

SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms

SHP2 Inhibition Suppresses RAS-ERK Signaling, the Development of JAK2 Inhibitor Persistence, and MPN Development in Pre-Clinical Models of Myeloproliferative Neoplasms

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Email alerts

ASH Publications

American Society of Hematology

SHP2 Inhibition Enhances JAK2 Inhibitor Therapy in Preclinical Models of Myeloproliferative Neoplasms

SHP2 Inhibition Suppresses RAS-ERK Signaling, the Development of JAK2 Inhibitor Persistence, and MPN Development in Pre-Clinical Models of Myeloproliferative Neoplasms

The Persistent Survival of MPN Cells to JAK2 Inhibition Is Dependent on SHP2 Activity, Which May Provide a Therapeutic Target to Enhance Current Anti-MPN Therapies

Targeting Insulin-like Growth Factor/Insulin Receptor Signaling to Overcome JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

The Pan-PIM Inhibitor INCB053914 Displays Potent Synergy at Low Doses in Combination with Ruxolitinib in Pre-Clinical Models of MPNs

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only